Vivesto presents interim report for Q2 2026
The report shows an operating result of -8.6 MSEK as well as positive clinical developments for Paccal Vet and Cantrixil.
See the latest news and media coverage for Vivesto. We track all announcements, press releases, and industry mentions in real time, all in one place.
Swedish human and veterinary oncology drug development company
vivesto.comLast updated
In short: Vivesto reported positive Paccal Vet data, advanced Cantrixil, and narrowed its Q2 loss.
The report shows an operating result of -8.6 MSEK as well as positive clinical developments for Paccal Vet and Cantrixil.
The study determined the maximum tolerated dose, with anti-tumor effects observed in 21 cats.
Topline results expected Q3 2026. The study evaluates Paccal Vet in dogs with splenic hemangiosarcoma.
The study shows Cantrixil was well tolerated intravenously in dogs, supporting development toward Phase I in AML.
Aug. 13 Vivesto narrowed its loss in the second quarter, CEO says: we are staying on plan FW Aug. 13 Vivesto AB Reports Earnings Results...
Solna, Sweden, September 15, 2026 - Vivesto AB, an oncology-focused development company, today announced positive topline results from its open label clinical pilot study evaluating...
Close The stock exchange opens green - Embracer surges on report. Market watch with Helena Yohannes Magnusson The drug development company Vivesto reports a reduced loss in the second quarter, while...
Visit a quote page and your recently viewed tickers will be displayed here.
Track Vivesto and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Vivesto and other trending companies.